Despite earlier failure, Roche doggedly presses on with MorphoSys Alzheimer’s candidate – FierceBiotech

March 7, 2017 by  
Filed under Alzheimers News

Sponsored By

FierceBiotech
Despite earlier failure, Roche doggedly presses on with MorphoSys Alzheimer's candidate
FierceBiotech
Roche is planning new trials of its Alzheimer's disease (AD) drug gantenerumab, despite an earlier phase 3 failure and a rising body count among other drugs targeting amyloid beta. Gantenerumab's original developer Morphosys says its Big Pharma partner …

and more »

More Info: Click here

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!

*